ROCHE HOLDING LTD S/ADR - RHHBY STOCK NEWS

Welcome to our dedicated page for ROCHE HOLDING S/ADR news (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on ROCHE HOLDING S/ADR stock.

Roche Holdings Ltd. S/ADR (RHHBY) is a leading biotechnology company with a global presence in the field of in-vitro diagnostics. Roche focuses on scientific excellence to develop medicines and diagnostics for improving and saving lives. The company's pivotal role in personalized healthcare is reflected in its commitment to transforming healthcare delivery. Roche's innovative approach encompasses the discovery and development of cutting-edge treatments, including the first CD20xCD3 bispecific antibody, Columvi® (glofitamab), for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company's recently FDA-cleared whole-slide imaging system, VENTANA DP 200, signifies Roche's dedication to revolutionizing pathology workflows through digitalization and artificial intelligence-based tools, ensuring pathologists can provide accurate and timely diagnoses. Roche's extensive portfolio and pipeline of haematology medicines demonstrate its unwavering commitment to advancing treatment options for patients worldwide.

09/07/2023 07:00 AM

News

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease

Rhea-AI Summary

Roche and Alnylam's Phase 2 study of zilebesiran meets primary endpoint with a greater than 15 mmHg reduction in systolic blood pressure at three months

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.19%

Tags

09/06/2023 01:00 AM

News

FDA Accepts Application for Genentech’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition

Rhea-AI Summary

Genentech's Biologics License Application for crovalimab, a novel anti-C5 recycling monoclonal antibody for the treatment of PNH, has been accepted by the FDA. Crovalimab achieved disease control and was well-tolerated in the Phase III COMMODORE 2 study. It could provide an option for self-administration every four weeks, reducing clinic visits for PNH patients. Crovalimab is being investigated in a broad clinical development program.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.31%

Tags

09/05/2023 01:00 AM

News

Economist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare

Rhea-AI Summary

The Economist Impact report commissioned by Roche Diagnostics reveals that integrating digital health technologies into healthcare systems remains challenging, but all countries surveyed have some foundations in place. Data privacy concerns and stakeholder collaboration are key factors for the future of digital health technology.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.82%

Tags

09/01/2023 01:00 AM

News

Roche’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer

Rhea-AI Summary

Roche's Phase III ALINA study shows that Alecensa reduces disease recurrence in early-stage ALK-positive non-small cell lung cancer (NSCLC), potentially providing a new treatment option for patients.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.3%

Tags

09/01/2023 01:00 AM

News

Genentech’s Alecensa Delivers Unprecedented Phase III Results for People With ALK-Positive Early-Stage Lung Cancer

Rhea-AI Summary

Genentech's Alecensa reduces disease recurrence in early-stage ALK-positive NSCLC, meeting primary endpoint in Phase III study

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.3%

Tags

08/29/2023 05:00 AM

News

Roche’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes

Rhea-AI Summary

Tecentriq SC approved in Great Britain for all indications, offering faster and more convenient treatment option. Tecentriq SC saves time and resources, with injection taking approx. 7 minutes compared to 30-60 minutes for IV infusion. Multiple oncology studies show preference for SC administration. Regulatory approvals ongoing globally. IMscin001 study shows comparable levels of Tecentriq in blood and consistent safety and efficacy profile with IV formulation.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.34%

Tags

08/29/2023 01:00 AM

News

European Commission approves Roche’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)

Rhea-AI Summary

Roche's Evrysdi receives EU approval for treating SMA in all ages, including babies from birth

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.34%

Tags

08/23/2023 01:43 AM

News

Genentech Provides Update on Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer

Rhea-AI Summary

Genentech (RO, ROG; RHHBY) inadvertently discloses interim analysis of SKYSCRAPER-01 study on tiragolumab plus Tecentriq for NSCLC treatment. Overall survival estimates: 22.9 months in tiragolumab plus Tecentriq arm, 16.7 months in Tecentriq monotherapy arm. No new safety signals found.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

4.34%

Tags

08/23/2023 01:22 AM

News

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer

Rhea-AI Summary

Roche (RO, ROG; RHHBY) has disclosed the second interim analysis of the Phase III SKYSCRAPER-01 study evaluating tiragolumab plus Tecentriq as a first-line treatment for NSCLC. The study remains blinded and ongoing. The interim results showed a median overall survival of 22.9 months for tiragolumab plus Tecentriq and 16.7 months for Tecentriq alone, with a hazard ratio of 0.81. No new safety signals were identified.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

4.34%

Tags

08/17/2023 01:00 AM

News

Roche launches a new addition to the cobas® connection modules, the CCM Vertical, helping to improve laboratory efficiency

Rhea-AI Summary

Roche has announced the extension of its cobas® connection modules (CCM) sample conveyors system with the newly developed CCM Vertical, allowing transportation of samples on overhead conveyors. This modular and flexible solution optimizes laboratory space and enables the transport of samples to adjacent floors or rooms, addressing the space limitations in laboratories.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.35%

Tags

FAQ

What is the current stock price of ROCHE HOLDING S/ADR (RHHBY)?

The current stock price of ROCHE HOLDING S/ADR (RHHBY) is $35 as of December 26, 2024.

What is the market cap of ROCHE HOLDING S/ADR (RHHBY)?

The market cap of ROCHE HOLDING S/ADR (RHHBY) is approximately 235.1B.

What is Roche Holdings Ltd. S/ADR (RHHBY) known for?

Roche is a global leader in biotechnology, specializing in in-vitro diagnostics and the development of cutting-edge medicines.

What is the significance of Columvi® (glofitamab) in Roche's portfolio?

Columvi® (glofitamab) is the first CD20xCD3 bispecific antibody that has shown promising results in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

How does Roche contribute to personalized healthcare?

Roche aims to transform healthcare delivery by focusing on scientific excellence, data insights, and partnerships with stakeholders to provide tailored treatment options for patients.

What recent innovation has Roche introduced in digital pathology?

Roche's VENTANA DP 200 whole-slide imaging system, with FDA clearance, allows pathologists to review and interpret digital pathology images efficiently, facilitating remote diagnosis and collaboration.

What is Roche's approach to advancing haematology treatments?

Roche has a robust portfolio and pipeline of haematology medicines, including T-cell engaging bispecific antibodies like Columvi®, to address the diverse needs of patients with blood cancers.